FDA
-
-
-
-
-
-
-
Aytu BioScience (AYTU) Announces Submission of Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement
-
-
-
-
-
-
-
Aytu BioScience (AYTU) Continues Availability of Adzenys XR-ODT(R)
-
-
-
-
-
-
-
Aytu BioScience (AYTU) Granted Fourth Patent License for AR101/Enzastaurin
-
-
-
-
-
-
-
Aytu BioPharma Announces Pricing of Public Offering
-
-
-
-
-
-
-
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Aytu Biosciences (AYTU) at Overweight, $11 PT, Sees it as Positive Development Potentially Extending ADHD Franchise Revenue Runway
-
-
-
-
-
-
-
Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering
-
249,540 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All